Search results
Results from the WOW.Com Content Network
In 2012, the FDA approved the drug for use as pre-exposure prophylaxis (PrEP), based on growing evidence that the drug was safe and effective at preventing HIV in populations at increased risk of infection. [41] The FDA has approved two additional medications for PrEP since then, approving Descovy in 2019 and Cabotegravir (Apretude) in 2021. [4 ...
HIV Medicine is a bimonthly peer-reviewed medical journal covering HIV/AIDS research. It was established in 1999 and is published by Wiley-Blackwell on behalf of the British HIV Association, of which it is the official journal. It is also the official journal of the European AIDS Clinical Society and the Australasian Society for HIV Medicine. [1]
AIDS-defining clinical conditions (also known as AIDS-defining illnesses or AIDS-defining diseases) is the list of diseases published by the Centers for Disease Control and Prevention (CDC) that are associated with AIDS and used worldwide as a guideline for AIDS diagnosis. CDC exclusively uses the term AIDS-defining clinical conditions, but the ...
Mount Sinai Journal of Medicine: Medicine: John Wiley & Sons: English: 1934–2012 Movement Disorders: Neurology: Wiley-Liss: English: 1986–present Myanmar Medical Journal: Medicine: Myanmar Medical Association: English: 1953–present Nano Biomedicine and Engineering: Medicine: Open-Access House of Science and Technology: English: 2009–present
The guidelines use new criteria to consider starting HAART, as described below. However, there remain a range of views on this subject and the decision of whether to commence treatment ultimately rests with the patient and his or her doctor. [citation needed] The US DHHS guidelines (published April 8, 2015) state: [citation needed]
The Society sponsors the HIV Medicine Association (HIVMA), an organization of HIV researchers and specialists, and funds research fellowships for junior investigators in infectious diseases. [6] With the support of a CDC grant IDSA entertains a listserv for infectious disease physicians called Emerging Infections Network.
The CDC recommends PEP for any HIV-negative person who has recently been exposed to HIV for any reason. [22] To be most effective, treatment should begin within an hour of exposure. [23] After 72 hours PEP is much less effective, and may not be effective at all. [22] Prophylactic treatment for HIV typically lasts four weeks. [22] [24]
HIV prevention refers to practices that aim to prevent the spread of the human immunodeficiency virus (HIV). HIV prevention practices may be undertaken by individuals to protect their own health and the health of those in their community, or may be instituted by governments and community-based organizations as public health policies.